Current status of colorectal cancer therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In 2004, the American Cancer Society estimated that approx 150,000 new cases of colorectal cancer would occur in the United States and that more than 57,000 Americans would die of the disease, making it the second most common cause of cancer-related death (1). Despite improvements in screening techniques, 30-40% of patients with colorectal cancer present with locoregionally advanced or metastatic disease and are not candidates for potentially curative therapy. Overall, progress in the surgical and neoadjuvant/adjuvant management of locally confined colorectal cancer has been rapid and very encouraging over the past several years. In addition, median survival in advanced disease has improved almost fourfold, as several new and active salvage systemic agents have emerged and been rapidly integrated into first-line regimens.

Original languageEnglish (US)
Title of host publicationEndoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management
PublisherHumana Press
Pages273-285
Number of pages13
ISBN (Print)158829532X, 9781588295323
DOIs
StatePublished - 2006

Fingerprint

Colorectal Neoplasms
Therapeutics
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Strother, J., Billingsley, K., Hung, A., & Blanke, C. (2006). Current status of colorectal cancer therapy. In Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management (pp. 273-285). Humana Press. https://doi.org/10.1007/978-1-59745-172-7_23

Current status of colorectal cancer therapy. / Strother, John; Billingsley, Kevin; Hung, Arthur; Blanke, Charles.

Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management. Humana Press, 2006. p. 273-285.

Research output: Chapter in Book/Report/Conference proceedingChapter

Strother, J, Billingsley, K, Hung, A & Blanke, C 2006, Current status of colorectal cancer therapy. in Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management. Humana Press, pp. 273-285. https://doi.org/10.1007/978-1-59745-172-7_23
Strother J, Billingsley K, Hung A, Blanke C. Current status of colorectal cancer therapy. In Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management. Humana Press. 2006. p. 273-285 https://doi.org/10.1007/978-1-59745-172-7_23
Strother, John ; Billingsley, Kevin ; Hung, Arthur ; Blanke, Charles. / Current status of colorectal cancer therapy. Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management. Humana Press, 2006. pp. 273-285
@inbook{f8fee2e4f0fa42b49ec7d138718122ae,
title = "Current status of colorectal cancer therapy",
abstract = "In 2004, the American Cancer Society estimated that approx 150,000 new cases of colorectal cancer would occur in the United States and that more than 57,000 Americans would die of the disease, making it the second most common cause of cancer-related death (1). Despite improvements in screening techniques, 30-40{\%} of patients with colorectal cancer present with locoregionally advanced or metastatic disease and are not candidates for potentially curative therapy. Overall, progress in the surgical and neoadjuvant/adjuvant management of locally confined colorectal cancer has been rapid and very encouraging over the past several years. In addition, median survival in advanced disease has improved almost fourfold, as several new and active salvage systemic agents have emerged and been rapidly integrated into first-line regimens.",
author = "John Strother and Kevin Billingsley and Arthur Hung and Charles Blanke",
year = "2006",
doi = "10.1007/978-1-59745-172-7_23",
language = "English (US)",
isbn = "158829532X",
pages = "273--285",
booktitle = "Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management",
publisher = "Humana Press",

}

TY - CHAP

T1 - Current status of colorectal cancer therapy

AU - Strother, John

AU - Billingsley, Kevin

AU - Hung, Arthur

AU - Blanke, Charles

PY - 2006

Y1 - 2006

N2 - In 2004, the American Cancer Society estimated that approx 150,000 new cases of colorectal cancer would occur in the United States and that more than 57,000 Americans would die of the disease, making it the second most common cause of cancer-related death (1). Despite improvements in screening techniques, 30-40% of patients with colorectal cancer present with locoregionally advanced or metastatic disease and are not candidates for potentially curative therapy. Overall, progress in the surgical and neoadjuvant/adjuvant management of locally confined colorectal cancer has been rapid and very encouraging over the past several years. In addition, median survival in advanced disease has improved almost fourfold, as several new and active salvage systemic agents have emerged and been rapidly integrated into first-line regimens.

AB - In 2004, the American Cancer Society estimated that approx 150,000 new cases of colorectal cancer would occur in the United States and that more than 57,000 Americans would die of the disease, making it the second most common cause of cancer-related death (1). Despite improvements in screening techniques, 30-40% of patients with colorectal cancer present with locoregionally advanced or metastatic disease and are not candidates for potentially curative therapy. Overall, progress in the surgical and neoadjuvant/adjuvant management of locally confined colorectal cancer has been rapid and very encouraging over the past several years. In addition, median survival in advanced disease has improved almost fourfold, as several new and active salvage systemic agents have emerged and been rapidly integrated into first-line regimens.

UR - http://www.scopus.com/inward/record.url?scp=84891440140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891440140&partnerID=8YFLogxK

U2 - 10.1007/978-1-59745-172-7_23

DO - 10.1007/978-1-59745-172-7_23

M3 - Chapter

SN - 158829532X

SN - 9781588295323

SP - 273

EP - 285

BT - Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management

PB - Humana Press

ER -